Swedish Orphan Biovitrum AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was SEK 3,876 million compared to SEK 3,211 million a year ago. Net income was SEK 258 million compared to SEK 268 million a year ago. Basic earnings per share from continuing operations was SEK 0.87 compared to SEK 0.91 a year ago. Diluted earnings per share from continuing operations was SEK 0.86 compared to SEK 0.9 a year ago.
For the six months, sales was SEK 8,801 million compared to SEK 6,872 million a year ago. Net income was SEK 801 million compared to SEK 964 million a year ago. Basic earnings per share from continuing operations was SEK 2.71 compared to SEK 3.27 a year ago. Diluted earnings per share from continuing operations was SEK 2.69 compared to SEK 3.26 a year ago.